https://orcid.org/0000-0001-7143-6758
Figures & data
Figure 1 Leukocytes (WBC) and lymphocytes (Ly) trend during the treatment with mogamulizumab. Basal value: 12/02/2020. First cycle of mogamulizumab: 12/23/2020. Second cycle of mogamulizumab on 01/21/2021. End of mogamulizumab: 06/01/2021.
Figure 2 Right lesions of the leg before (A) and after (B) four cycles of mogamulizumab.
Figure 3 Diffuse erythema with scaling covering approximately 60% of BSA, onychodystrophy, ectropion, mild palmo-plantar hyperkeratosis.
Figure 4 Epidermotropic infiltrate with Pautrier’s microabscesses with atypical lymphocytes and a patchy lichenoid infiltrate in the papillary dermis.
Figure 5 Already after the first cycle of mogamulizumab the patient achieved prompt clinical response with >90% clearance of skin disease.
Figure 6 Skin involvement before (A) and after (B) therapy with mogamulizumab.
Figure 7 Cytogenetic abnormalities before and after mogamulizumab administration. After the first course of mogamulizumab, the hypothetraploid clone showed by karyotype and confirmed by FISH (A) was cleared and only a second clone remained detectable by FISH (B).
Figure 8 Mogamulizumab-induced lichenoid reaction developed after 15 infusions. An erythematous-desquamative, confluent lichenoid eruption mainly localized on the lower abdomen can be observed. Note how the eruption arose within healthy skin revealing the excellent response obtained by treatment.
Figure 9 Eruptive yellowish papules located on face and forehead. (A–C). Lesions on the forehead and the cheeks. (D). Dermoscopy showing the presence of well-demarcated yellow globule structures, divided by septa constituted by focused reddish capillaries.
